Give me more for this agreement: TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 ARTICLE 2 RIGHTS AND OBLIGATIONS 11 2.1 License Grants from Theravance to GSK 11 2.1.1 Development License 11 2.1.2 Commercialization License 11 2.1.3 Manufacturing License 11 2.2 Sublicensing and Subcontracting 11 2.3 Trademarks and Housemarks 12 2.3.1 Trademarks 12 2.3.2 Housemarks 12 2.3.3 Ownership of Inventions 12 ARTICLE 3 GOVERNANCE OF DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS 13 3.1 Joint Steering Committee 13 3.1.1 Purpose 13 3.1.2 Members; Officers 13 3.1.3 Responsibilities 13 3.1.4 Meetings 14 3.1.5 Decision-Making 14 3.2 Joint Project Committee 15 3.2.1 Purpose 15 3.2.2 Members; Officers 15 3.2.3 Responsibilities 15 3.2.4 Meetings 16 3.2.5 Decision-Making 16 3.3 Minutes of Committee Meetings 16 3.3.1 Distribution of Minutes 16 3.3.2 Review of Minutes 16 3.3.3 Discussion of Comments 16 3.4 Expenses 17
3.5 General Guidelines and Initial Coordination Efforts 17 ARTICLE 4 DEVELOPMENT OF PRODUCTS 17 4.1 Pooling of Compounds 17 4.2 Obligations for Development 17 4.2.1 General; GSK 17 4.2.2 GSK's Funding Responsibility 18 4.2.3 Decisions with Respect to Products 18 4.2.4 Development Timelines 18 4.3 Replacement Compounds 19 4.4 Transfer of Data 19 4.5 LABA Activity Inside and Outside of the Collaboration 19 i
 ARTICLE 5 COMMERCIALIZATION 20 5.1 Global Marketing Plans 20 5.1.1 General 20 5.1.2 Contents of Each Marketing Plan 20 5.2 Obligations for Commercialization 20 5.3 Commercialization 20 5.3.1 GSK Responsibility 20 5.3.2 Semi-Annual Reports 21 5.3.3 Exports to the United States 21 ARTICLE 6 FINANCIAL PROVISIONS 21 6.1 Signing Payment; Equity Investment; One-Time Fee 21 6.1.1 Signing Payment 21 6.1.2 Stock Purchase 21 6.1.3 One-Time Fee for AMI-15471 21 6.1.4 One-Time Fee for Each Theravance New Compound 22 6.2 Milestone Payments 22 6.2.1 General 22 6.2.2 GSK to Theravance 22 6.2.3 Theravance to GSK 23 6.2.4 Notification and Payment 24 6.3 Payment of Royalties on Net Sales 24 6.3.1 Royalty on Single-Agent Collaboration Products and LABA/ICS Combination Products 24 6.3.2 Royalty Adjustment 25 6.3.3 Royalties on Other Collaboration Products Launched After the LABA/ICS Combination Product 25 6.4 Royalty Responsibilities; Net Sales Reports 26 6.4.1 Payments to Third Parties 26 6.4.2 Net Sales Report 26 6.5 GAAP 26 6.6 Currencies 26 6.7 Manner of Payments 26 6.8 Interest on Late Payments 27
 6.9 Tax Withholding 27 6.10 Financial Records; Audits 27 ARTICLE 7 PROMOTIONAL MATERIALS AND SAMPLES 28 7.1 Promotional Materials 28 7.1.1 Review of Core Promotional Materials 28 7.1.2 Markings of Promotional Materials 28 7.2 Samples 28 7.3 Statements Consistent with Labeling 28 7.4 Implications of Change in Control in Theravance 28 ii
 ARTICLE 8 REGULATORY MATTERS 29 8.1 Governmental Authorities 29 8.2 Filings 29 8.3 Exchange of Drug Safety Information 29 8.4 Recalls or Other Corrective Action 29 8.5 Events Affecting Integrity or Reputation 29 ARTICLE 9 ORDERS; SUPPLY AND RETURNS 30 9.1 Orders and Terms of Sale 30 9.2 Supply of API Compound and Formulated Collaboration Product for Development 30 9.2.1 Supply of API Compound for Development 30 9.2.2 Supply of Formulated Collaboration Products for Development 30 9.3 Supply of API Compound for Commercial Requirements 30 9.4 Supply of Collaboration Products for Commercialization 30 9.5 Inventories 31 ARTICLE 10 CONFIDENTIAL INFORMATION 31 10.1 Confidential Information 31 10.2 Permitted Disclosure and Use 31 10.3 Publications 31 10.4 Public Announcements 32 10.5 Confidentiality of This Agreement 32 10.6 Termination of Prior Confidentiality Agreements 32 10.7 Survival 32 ARTICLE 11 REPRESENTATIONS AND WARRANTIES; COVENANTS 33 11.1 Mutual Representations and Warranties 33 11.2 Additional GSK Representations and Warranties 34 11.3 Additional Theravance Representations and Warranties 34 11.4 Covenants 35 11.5 Disclaimer of Warranty 35